← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 2
Valacyclovir (Valacyclovir)
GlaxoSmithKline·Metastatic Non-small Cell Lung Can…
ORR 20%·t½ 14 h
Overview
Program
Valacyclovir
Overview
Company
GlaxoSmithKline
Overview
Modality
ANTIBODY
Overview
Target
Metastatic Non-small Cell Lung Cancer
Overview
Indication
Metastatic Non-small Cell Lung Cancer; Metastatic Triple-negative Breast Cancer
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
MoA
Mechanism
of AXX-18 was found to be similar to that of oleanolic acid, except that AXX-18 could act on both the UL8 and UL52 proteins of the uncoupling helicase-primase enzyme, whereas oleanolic acid could only act on the UL8 pro
MoA
Biomarker
biomarkers for AD, a positive serum antibody test (IgG or IgM) for HSV-1 or HSV-2, and a Mini-Mental State Ex
PK/PD
Half-life
14 h
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
Refractory and/or Resistant Herpes Simplex Virus Mucocutaneous Infections in Adult Transplantation and Cellular Therapy Patients: A Single-Center Experience.. Purpose and methods Refractory and/or resistant herpes simplex virus (R/R HSV) mucocutaneous infections are an emerging challenge in immunocompromised hosts. A single-center retrospective study of R/R HSV mucocutaneous infections in allogene…
Clinical
Primary efficacy
ORR 20%
Clinical
ORR
20%
Clinical
Result source
ClinicalTrials.gov NCT00492050
Clinical
Data Tier / Score
A · 38
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 12일 (1일 전)